$1.09
0.00% yesterday
Nasdaq, Nov 15, 10:00 pm CET
ISIN
US75989R1077
Symbol
RNXT
Sector
Industry

RenovoRx Inc Stock price

$1.09
+0.10 10.09% 1M
-0.30 21.58% 6M
-1.20 52.40% YTD
+0.35 46.58% 1Y
-6.97 86.48% 3Y
-6.17 84.99% 5Y
-6.17 84.99% 10Y
Nasdaq, Closing price Fri, Nov 15 2024
+0.00 0.00%
ISIN
US75989R1077
Symbol
RNXT
Sector
Industry

Key metrics

Market capitalization $26.15m
Enterprise Value $16.59m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 3.70
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-10.12m
Free Cash Flow (TTM) Free Cash Flow $-8.75m
Cash position $9.56m
EPS (TTM) EPS $-0.57
P/E forward negative
Short interest 0.31%
Show more

Is RenovoRx Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

RenovoRx Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a RenovoRx Inc forecast:

3x Buy
100%

Analyst Opinions

3 Analysts have issued a RenovoRx Inc forecast:

Buy
100%

Financial data from RenovoRx Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 4.89 4.89
20% 20%
-
- Research and Development Expense 5.22 5.22
8% 8%
-
-10 -10
14% 14%
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -10 -10
14% 14%
-
Net Profit -9.16 -9.16
0% 0%
-

In millions USD.

Don't miss a Thing! We will send you all news about RenovoRx Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

RenovoRx Inc Stock News

Neutral
GlobeNewsWire
one day ago
Near-Term Revenue Potential with Commercialization Plan for FDA-Cleared RenovoCath® Delivery System in Both Direct and Commercial Partner Channels Renowned Clinical Oncology Sites Participating in Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial; Trial Moving Towards Next Interim Analysis and Full Enrollment As of September 30, 2024, the Company had $9.6 million in Cash, Sufficient to Fund Op...
Neutral
GlobeNewsWire
about 2 months ago
Company expands relationship with manufacturing partner Medical Murray, and continues active exploration of standalone opportunities for RenovoCath Company expands relationship with manufacturing partner Medical Murray, and continues active exploration of standalone opportunities for RenovoCath
Neutral
GlobeNewsWire
about 2 months ago
Published data shows that chemotherapy delivered via TAMP with prior chemoradiation in Locally Advanced Pancreatic Cancer observed an Overall Survival of 27-months Published data shows that chemotherapy delivered via TAMP with prior chemoradiation in Locally Advanced Pancreatic Cancer observed an Overall Survival of 27-months
More RenovoRx Inc News

Company Profile

RenovoRx, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for the local treatment of solid tumors. Its therapy platform, RenovoRx, handles the optimizing drug concentration in solid tumors using approved small molecule chemotherapeutics that enable physicians to isolate segments of the vascular anatomy closest to tumors and force chemotherapy across the blood vessel wall to bathe these difficult-to-reach tumors in chemotherapy. The company was founded by Ramtin Agah and Kamran Najmabadi in December 2009 and is headquartered in Los Altos, CA.

Head office United States
CEO Shaun Bagai
Employees 8
Founded 2009
Website www.renovorx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today